Novo Nordisk reported earnings, posting some chunky year-over-year growth and far outperforming its only real rival at the ...

Novo Nordisk (NVO) and Eli Lilly (LLY) manufacture the top three weight loss drugs on the market, but heightened demand is ...

Novo said supply of Wegovy and Ozempic is in good shape after the drugs were removed from the FDA’s shortage list last week.

With a gain of more than 531% over the last 12 months, shares of Viking Therapeutics (NASDAQ: VKTX) are a hot commodity, to ...

BEN Shephard awkwardly stepped in on today’s This Morning when former politician Nadine Dorries repeatedly plugged a ...

Shares in Novo Nordisk which competes with Eli Lilly in an obesity drug market that some analysts forecast could be worth about $150 billion by the early 2030s, rose nearly 9%.

At least 25% body weight loss occurred in 43% taking the highest dose ... Jastreboff reported disclosures with Amgen, ...

Healthcare giant Eli Lilly (NYSE: LLY) has been trading at an inflated valuation for some time thanks to excitement around ...

Novo Nordisk reported mixed Q3 earnings, but GLP-1 drugs contributed to revenue strength. The company also adjusted its ...

Novo Nordisk reported better-than-expected third-quarter sales for its weight-loss drug Wegovy, calming investor concerns ...

Novo Nordisk (NVO) posts Q3 sales for its weight loss drug Wegovy, contrasting rival Eli Lilly's (LLY) quarterly miss for its obesity drug, Zepbound. Read more here.

Novo Nordisk reported strong sales for its weight-loss drug Wegovy, surpassing analyst expectations and calming investor ...